1 Reason to Sell Moderna Now

When attempting to gauge whether or not the management of a company has the same priorities as its investors, one metric you ought to consider is the percentage of shares owned by insiders. Insiders sell their stock for many reasons, but when executives are exiting their stakes as fast as they can, it should raise some eyebrows.

Moderna (NASDAQ: MRNA) has experienced a renaissance since the COVID-19 pandemic intensified in March. The stock, trading under $20 per share in February, has several times approached or exceeded $80 in the months since. However, company executives aren't waiting to see what happens with their coronavirus vaccine candidate: Instead, they are taking advantage and cashing in.

Several hundred dollar bills fanned out with a coronavirus mask over them.

Image source: Getty Images

There have been no insider stock buys and 81 sales in September and October at share prices between $60 and $80. In fact, since May, insiders have sold 2.12 million shares without making a single purchase. Notably, Moderna also first announced positive data from its early coronavirus vaccine trials in May. It can be logical for an executive to sell shares when a significant portion of their net worth is tied up in company stock. Such transactions can be executed under what is known as a 10b5-1 plan -- a pre-scheduled plan to sell shares that helps shield the seller from accusations of insider trading. Despite having these plans set up, NPR found multiple executives had modified or initiated their 10b5-1 plans shortly before key information was released publicly. Further, some Moderna executives, including the chief medical officer, have sold every share they own.

Moderna executives have faced some tough questions about their stock sales, but the selling hasn't slowed. Its chief corporate affairs officer has even defended the sales and the modified sale plans, asserting that the company has strict policies in place to prevent insider trading.

Most of us are hoping an effective COVID-19 vaccine will be approved and reach the public soon. Investors interested in buying shares in the companies working to produce one may want to take a cue from Moderna's executives and choose a different company's stock.

10 stocks we like better than Moderna INC
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More